The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children: a Prospective, Randomized Crossover Trial

This study is a multicenter, randomized controlled crossover trial aimed to evaluate the efficacy and safety of dapagliflozin in the treatment of hereditary kidney disease with proteinuria in children

Start Date21 Mar 2025

Sponsor / Collaborator

Paediatrics Hospital Affiliated To Fudan University

[+8]

ChiCTR2500096068

/ SuspendedEarly Phase 1IIT

Ultrasound in the Diagnosis and Treatment of Fractures in Children's Extremities

Start Date16 Jan 2025

Sponsor / Collaborator

Wuhan Children's Hospital

ChiCTR2500099334

/ CompletedNot ApplicableIIT

Clinical features and survival analysis of Langerhans histiocytosis in children

Start Date10 Nov 2024

Sponsor / Collaborator

Wuhan Children's Hospital

100 Clinical Results associated with Wuhan Children's Hospital

0 Patents (Medical) associated with Wuhan Children's Hospital

464

Literatures (Medical) associated with Wuhan Children's Hospital

01 Jun 2025·Seminars in Arthritis and Rheumatism

Development of a prediction model for poor prognosis in childhood-onset Takayasu's arteritis

Article

Author: Zhu, Jia ; Wang, Lian ; Kang, Min ; He, Baoping ; Xu, Yingjie ; Li, Ming ; Li, Xiaohui ; Chu, Weihong ; Su, Gaixiu ; Liu, Fan ; Yue, Tong ; Zhang, Dan ; Niu, Wenquan ; Lai, Jianming ; Zhao, Xue

OBJECTIVESChildhood-onset Takayasu's arteritis (cTAK) is a rare disease with high recurrence rates, vascular complications, and mortality. This study aimed to identify the risk factors for poor prognosis in hospitalized patients with cTAK and develop a nomogram prediction model.METHODSThis was a prospective longitudinal multicenter cohort study. Cohorts were categorized into poor and good prognosis groups according to follow-up outcomes. Poor prognosis included vascular complications, disease recurrence, persistent non-remission, and cTAK-related death.RESULTSOf the 111 patients, 73 (65.8%) and 38 (34.2%) were categorized into the good and poor prognosis groups, respectively, with a median follow-up of 36.0 [24.0, 60.0] months. Seven independent factors for poor prognosis of cTAK were identified: the Indian Takayasu Clinical Activity Score with the Acute-Phase Response (ITAS.A), internal carotid artery stenosis, external carotid artery stenosis, aortic insufficiency, mitral insufficiency, tricuspid insufficiency, and hypertensive heart disease (odds ratios: 1.20, 3.21, 3.57, 3.88, 9.08, 15.67, and 7.42, respectively; all P values < 0.05). The nomogram prediction model yielded an area under the receiver operating characteristic curve of 0.79. The C-index of the nomogram constructed based on the prediction model was 0.73. The accuracy of this model was 67.0% after bootstrapping for 1000 repetitions.CONCLUSIONWe used easily accessible clinical and laboratory data to establish a nomogram model for predicting the probability of poor prognosis with hospitalized cTAK patients.

01 May 2025·Acta Physiologica

Identification of a new gain‐of‐function variant p.N536Y of KCNMA1 associated with PNKD3 in the Chinese population

Author: Liang, Lina ; Gao, Feng ; Huang, Yufeng ; Wang, Qing K. ; He, Xuelian ; Liu, Yin ; Xu, Xuebin

09 Apr 2025·ACS Applied Materials & Interfaces

Combining CRISPR-Cas12a with Microsphere Array-Enhanced Fluorescence for Portable Pathogen Nucleic Acid Detection

Article

Author: Xi, Xiaodan ; Zeng, Zhikun ; Wang, Fubing ; Yang, Chen ; Chen, Liangjun ; Yuan, Chunhui ; Gao, Menglu ; Yang, Yi ; Si, Wu ; Rong, Yuan

The detection of food contamination in a swift and sensitive manner is essential for safeguarding public health. Clustered regularly interspaced short palindromic repeats (CRISPR)-based assays for nucleic acid detection are renowned for their high specificity and convenient, related studies have focused on refining the Cas protein and optimizing the CRISPR (cr)RNAs design within CRISPR-based assays for enhancing the sensitivity of nucleic acid detection. Our research offers innovative insights into enhancing the fluorescence signal output intensity from a physical standpoint, thereby presenting a practical and cost-effective strategy to lower the detection thresholds in CRISPR-based assays. By a layer of microsphere arrays was spread onto the bottom of the microfluidic chip to enhance the fluorescence signal of the sample via self-assembly of the microspheres. Recombinase polymerase amplification (RPA) was used to amplify target sequences, followed by crRNA binding to activate Cas enzyme, cleaving fluorescein amidite (FAM)-labeled reporters and emitting a fluorescent signal. The method successfully identified SARS-CoV-2 positive samples (10 clinical samples and 8 environmental contamination samples) and distinguished them from negative samples. Meanwhile, it successfully detected 4 food contamination Shigella samples and 5 clinical Shigella samples. In this study, the developed method exhibited a detection limit (LoD) of 75 fM for SARS-CoV-2 (POCT with USB camera: 50 fM) and 100 fM for Shigella (POCT with USB camera: 75 fM). It also demonstrated promising sensitivity (100%) and specificity (100%) in a small-sample validation. Combined portable and automated detection was achieved using a smartphone to receive and process the fluorescent signals obtained from the samples. The detection platform developed in this study is not only applicable for the detection of pathogens in cold-chain food products, but also extends to pathogen detection in community hospitals and resource-limited areas, providing an efficient solution for rapid pathogen screening in different settings. Moreover, different nucleic acid samples can be detected by changing the RPA primer and CRISPR crRNA. This method provides a paradigm for studying enhanced fluorescence signaling and holds significant potential to advance the commercialization and practical use of CRISPR fluorescence sensors.

100 Deals associated with Wuhan Children's Hospital

100 Translational Medicine associated with Wuhan Children's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 16 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Wuhan Children's Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 16 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing